Working… Menu

A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02138955
Recruitment Status : Unknown
Verified May 2017 by SignPath Pharma, Inc..
Recruitment status was:  Active, not recruiting
First Posted : May 15, 2014
Last Update Posted : May 9, 2017
Information provided by (Responsible Party):
SignPath Pharma, Inc.

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : June 2017
Estimated Study Completion Date : June 30, 2017